A new study in the journal Lancet finds that a vaccine could be on the way.
One-hundred-forty-eight lung cancer patients were divided into two groups. One group got chemotherapy plus the vaccine called TG4010. The rest were given chemotherapy alone.
After six months, 43 percent of those getting both treatments had slower progression of their cancer, compared to 35 percent of those who had only chemotherapy.
Overall survival was similar in both groups.
The combo therapy worked better in patients who had normal levels of so-called natural killer cells that work to fight cancer.
Another trial study is now under way.